3/17/23 *UPDATE*
Greetings Readers,
CMND needs to be back on radar this morning. Here’s why.
As yesterday played out, CMND could not sustain the early green burst that had it run to a high of $4.15 Thursday.
When the closing bell rang, CMND had pulled back towards the lower end of its 52-week range.
But that’s where things could get interesting. Follow closely.
The last time CMND was trading at or around this level was just a few days ago. And from there, it went on a vertical chart surge north of $5.00.
Now, this move was partly due to the volatility potential created from CMND’s low float of approximately 1.09Mn shares.
And in case you didn’t see it, the company dropped some huge news:
Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder.
Dr. Adi Zuloff-Shani, Clearmind’s CEO, shared:
“From studies with MEAI, we believe it has potential to break the vicious drinking cycle at the point of the decision to drink more alcohol, by potentially innervating neural pathways that lead to sensible behavior. Globally, AUD causes many Bn’s of dollars in healthcare costs and millions of deaths each year. The IND submission to FDA, to initiate our clinical trial, is a milestone showing the huge commitment of the Clearmind team to finding a solution to this abusive disorder. We’re thrilled to be a step closer to helping patients with severely unmet medical needs.“
Take a second now to catch your breath, but don’t take too long to get CMND back on radar this morning.
Sincerely,
Virtus Junxit
3/16/23 *Morning UPDATE*
Greetings Readers,
CMND is making waves early. Got your eyes on the target?
If not, let me fill you in. After CMND hit a high of $4.15 early, it is still significantly off this week’s $5.00+ high it hit on Monday.
But why is it trading green first thing today?
Most of the attention on this Nasdaq breakout idea could be coming from this: Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder
On top of this important press release, CMND trades above 4 key lines of potential support at the moment including its:
- 5-Day Simple Moving Average (SMA)
- 20-Day SMA
- 5-Day Exponential Moving Average (EMA)
- 13-Day EMA
Could these levels be building support for CMND to try and run down previous highs? You’ll want to watch these closely towards the end of this week.
If you haven’t yet, read my initial report and get CMND on radar quickly today.
Sincerely,
Virtus Junxit
3/16/23
Greetings Readers,
Let’s hunker down for a second because we’ve got a good bit to go over.
My alert for Monday put together a solid two-day outing. From a $.7975 open on Monday, it surged to a high of $.9345 Tuesday (new 1.5 month high).
Overall, that short term blast resulted in my Nasdaq profile moving approximately 17% to get the week kicked off.
Solid stuff. But I now want to get you to turn your attention towards a past champ Nasdaq idea this very second.
And not to toot my own horn, but it has put together a combined 50+% (approx.) in short term runs after being alerted.
What could be on tap next for this Nasdaq Biotech?
Well, with a tiny float (fewer than 2Mn shares), an explosive chart history filled with several short term $1.00+ rips, and multiple big-time announcements already in 2023, the world could be this past champ’s oyster.
Drop everything and get *Clearmind Medicine Inc. (CMND)* back on your radar now.
Clearmind is a psych-e-delic pharmaceutical biotech company focused on the discovery and development of novel psych-e-delic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psych-e-delic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
Discover How Clearmind Medicine Inc. Is Developing Innovative Psych-e-delic-Based Medicines For Treating Addiction & Mental Health.
Clearmind Medicine Inc.’s primary objective is to research and develop psych-e-delic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of seven patent families.
Clearmind Medicine Inc. intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Clearmind’s flagship treatments are focused on Alcohol Use Disorder (AUD), which is incredibly common. It varies from mild to excessive, and describes a person’s inability to restrict their alcohol consumption, despite negative social, occupational, or health consequences.
Alcohol Use Disorder (AUD) encompasses conditions that are referred to as alcohol abuse, alcohol dependence, alcohol addiction, and alcoholism. (1)
AUD is a medical condition characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences.
Considered a brain disorder AUD can be mild, moderate, or severe.
The good news is that no matter how severe the problem may seem, evidence-based treatment with behavioral therapies, mutual-support groups, and/or medications can help people with AUD achieve and maintain recovery.(2)
According to a national survey, 14.1 million adults ages 18 and older (5.6% of this age group) had AUD in 2019.
Among youth, an estimated 414,000 adolescents ages 12–17 (1.7% of this age group) had AUD during this timeframe.
What increases the risk for AUD? A person’s risk for developing AUD depends, in part, on how much, how often, and how quickly they consume alcohol.
Alcohol misuse, which includes binge drinking and heavy alcohol use, over time increases the risk of AUD.
Other factors also increase the risk of AUD, such as:
Drinking at an early age. A recent national survey found that among people ages 26 and older, those who began drinking before age 15 were more than 5 times as likely to report having AUD in the past year as those who waited until age 21 or later to begin drinking. The risk for females in this group is higher than that of males.
Genetics and family history of alcohol problems. Genetics play a role, with heritability approximately 60 percent; however, like other chronic health conditions, AUD risk is influenced by the interplay between a person’s genes and their environment. Parents’ drinking patterns may also influence the likelihood that a child will one day develop AUD.
Mental health conditions and a history of trauma. A wide range of psychiatric conditions—including depression, post-traumatic stress disorder, and attention deficit hyperactivity disorder—are comorbid with AUD and are associated with an increased risk of AUD. People with a history of childhood trauma are also vulnerable to AUD.
The Solution
Breaking the Cycle
Clearmind Medicine Inc. believes that MEAI breaks the vicious binge-drinking cycle at the decision point to drink more alcohol,by potentially innervating neural pathways such as 5-HT1A that lead to “sensible behavior.”
Non-Addictive
Anecdotal reports and pre-clinical in-vivo results indicate on the self-limiting property of MEAI—unlike traditional treatments.
Expansive Potential
The literature shows that 5-HT1A receptors are associated with controlling craving behavior across the board. This indicates that MEAI may have a wide range of applications beyond binge drinking.
Find more important details in the company presentation.
—–
Key Pressing Details – Potential CMND Catalysts To Know Right Now
No. 1: CMND has a tiny float.
Like, really small.
According to Yahoo Finance, CMND has a float in the neighborhood of 1.09Mn shares.
Why is this important? Simple. When a profile has these few shares available, the potential for volatility needs to be noted…
… And noted on a daily basis. If a potential catalyst, like positive news, comes out on a profile with such few shares, the volatility can be enough to make your head spin.
—–
No. 2: CMND has already made a handful of huge announcements early in 2023 that could start grabbing Wall Street’s attention.
Chew on these:
Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ket-a-mine-Based Compound
Clearmind’s CEO, Dr. Adi Zuloff-Shani, shared:
“One of our goals of working closely with leading researchers around the world, is to investigate our proprietary compounds for new revolutionary treatments for addictions and mental health disorders. Our strong IP portfolio includes numerous innovative compounds in the field of psych-e-delic-derived therapeutics. We are very encouraged by these preclinical data as we believe this could make a tremendous difference to patients suffering with treatment-resistant depression, who have limited options available to them.”
Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
Clearmind’s CEO Dr. Adi Zuloff-Shani, PhD, said:
“We continue to expand our work with SciSparc in an effort to expand the mental health therapy toolbox so we can offer patients safer and more effective treatments. Previous studies we have performed with MEAI and PEA suggested that combining the two allowed us to reduce doses of MEAI while maintaining efficacy levels.
The new patent applications aim to utilize psych-e-delic substances that have shown positive clinical results and to combine them with CannAmide, to potentially offer a treatment that is more effective, safer, and at lower costs. This strategy aligns with the company’s vision to bring patients the newest, most effective treatments while maintaining a high safety profile and a strong IP position to enhance commercial viability.“
—–
No. 3: How About An Explosive Chart History?
Here’s CMND’s recent 3-month chart. Check it out:
What do you see above? I’ll tell you what I see.
Multiple $1.00+ intraday and short term pops.
Here’s a few examples:
12/14/22: From a $3.18 close, CMND cruised to a $5.10 high one day later for a 60% short term move.
1/6/23: Opening at $3.26, CMND hit a high of $4.75 one session later for a 45% short term run.
3/10/23: On the morning of the 10th, CMND hit a low of $3.20 before rocketing to $5.04 the next session for a short term run of 57.5%.
Like I said, explosive.
—–
Don’t waste too much time getting past champ Clearmind Medicine Inc. (CMND) back on radar now.
Talk soon.
Sincerely,
Virtus Junxit
